- BNF:
- Not listed
- Status:
- Red
- Decision Date:
- August 2016
Comments
RED:
- NICE HST3: for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. (Decision date - August 2016).
- HST22 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. (Decision date - March 2023)
NHS England drug - to be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again